Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance

Stock Track

Oct 30

Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly outperformed analyst expectations, demonstrating strong growth and improved financial health.

The company reported Q3 revenue of $49.5 million, beating the consensus estimate of $46.5 million and marking a substantial 25% increase quarter-over-quarter. This growth was primarily driven by a 28% rise in filled VOQUEZNA prescriptions, supported by strategic sales force retargeting efforts. Phathom's adjusted earnings per share (EPS) also exceeded expectations, coming in at -$0.15 compared to the estimated -$0.56, representing a 72.48% beat.

In light of these strong results, Phathom Pharmaceuticals has updated its full-year 2025 revenue guidance to $170-$175 million, up from the previous range of $165-$175 million. The company also reported significant cost savings, with cash operating expenses down 43% quarter-over-quarter, aligning with its cost-saving plans. These factors, combined with stable commercial coverage for over 80% of U.S. lives, have contributed to the positive market reaction and heightened investor confidence in Phathom's growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137667451"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137667451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137667451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137667451","market":"us","top_or_hot":-1,"title":"Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly outperformed analyst expectations, demonstrating strong growth and improved financial health.</p>\n\n<p>The company reported Q3 revenue of $49.5 million, beating the consensus estimate of $46.5 million and marking a substantial 25% increase quarter-over-quarter. This growth was primarily driven by a 28% rise in filled VOQUEZNA prescriptions, supported by strategic sales force retargeting efforts. Phathom's adjusted earnings per share (EPS) also exceeded expectations, coming in at -$0.15 compared to the estimated -$0.56, representing a 72.48% beat.</p>\n\n<p>In light of these strong results, Phathom Pharmaceuticals has updated its full-year 2025 revenue guidance to $170-$175 million, up from the previous range of $165-$175 million. The company also reported significant cost savings, with cash operating expenses down 43% quarter-over-quarter, aligning with its cost-saving plans. These factors, combined with stable commercial coverage for over 80% of U.S. lives, have contributed to the positive market reaction and heightened investor confidence in Phathom's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-30 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly outperformed analyst expectations, demonstrating strong growth and improved financial health.</p>\n\n<p>The company reported Q3 revenue of $49.5 million, beating the consensus estimate of $46.5 million and marking a substantial 25% increase quarter-over-quarter. This growth was primarily driven by a 28% rise in filled VOQUEZNA prescriptions, supported by strategic sales force retargeting efforts. Phathom's adjusted earnings per share (EPS) also exceeded expectations, coming in at -$0.15 compared to the estimated -$0.56, representing a 72.48% beat.</p>\n\n<p>In light of these strong results, Phathom Pharmaceuticals has updated its full-year 2025 revenue guidance to $170-$175 million, up from the previous range of $165-$175 million. The company also reported significant cost savings, with cash operating expenses down 43% quarter-over-quarter, aligning with its cost-saving plans. These factors, combined with stable commercial coverage for over 80% of U.S. lives, have contributed to the positive market reaction and heightened investor confidence in Phathom's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1137667451","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137667451","pubTimestamp":1761833329,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"个股赛道|Phathom Pharmaceuticals因强劲Q3业绩飙升10.50%并上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals (NASDAQ: PHAT) stock is soaring 10.50% in pre-market trading following the release of its impressive third-quarter 2025 financial results. The pharmaceutical company significantly outperformed analyst expectations, demonstrating strong growth and improved financial health.\nThe company reported Q3 revenue of $49.5 million, beating the consensus estimate of $46.5 million and marking a substantial 25% increase quarter-over-quarter. This growth was primarily driven by a 28% rise in filled VOQUEZNA prescriptions, supported by strategic sales force retargeting efforts. Phathom's adjusted earnings per share (EPS) also exceeded expectations, coming in at -$0.15 compared to the estimated -$0.56, representing a 72.48% beat.\nIn light of these strong results, Phathom Pharmaceuticals has updated its full-year 2025 revenue guidance to $170-$175 million, up from the previous range of $165-$175 million. The company also reported significant cost savings, with cash operating expenses down 43% quarter-over-quarter, aligning with its cost-saving plans. These factors, combined with stable commercial coverage for over 80% of U.S. lives, have contributed to the positive market reaction and heightened investor confidence in Phathom's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}